Caricamento...
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
Tepotinib is a key drug for cancer patients with mesenchymal‐epithelial transition receptor tyrosine kinase proto‐oncogene (MET) exon 14 skipping mutation. However, its bioavailability in the cerebrospinal fluid (CSF) in humans has not been fully elucidated. Moreover, information about the efficacy...
Salvato in:
| Pubblicato in: | Cancer Commun (Lond) |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819565/ https://ncbi.nlm.nih.gov/pubmed/33387444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12124 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|